Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Recce Pharmaceuticals (RCE) has signed an agreement with clinical research organisation Parexel for the phase one clinical trial of its synthetic antibiotic, Recce 327
  • In animal trials, it has shown to be effective in treating sepsis and blood infections arising from certain bacteria
  • In addition, the broad-spectrum antibiotic has shown promise in working against superbugs and maintaining its potency with repeated use
  • The Phase 1 human trial will test the safety and tolerability of Recce 327 in 40 healthy participants
  • Dosing of participants is expected to occur in the second half of 2020 and results are expected in less than 12 months from now
  • By market close, Recce Pharmaceutical shares were up 1.39 per cent to 36.5 cents each

Recce Pharmaceuticals (RCE) has signed an agreement with clinical research organisation Parexel for the Phase 1 clinical trial of Recce 327.

In animal trials, the synthetic antibiotic has shown to be effective in treating sepsis and blood infections arising from Escherichia coli and Staphylococcus aureus bacteria. Furthermore, the broad-spectrum antibiotic has shown promise in the fight against antibiotic resistance, explains Chairman Dr John Prendergast.

“The formalisation of the clinical trial agreement is a major milestone towards advancing RECCE 327 through the clinic. It brings us a step closer to addressing the rising rates of antibiotic resistance, with a synthetic antibiotic that has shown an extraordinary preclinical potential to fight off a broad range of bacterial infections, including superbug forms, even with repeated use,” he said.

If it successfully completed all human trials, Recce 327 could fill the unmet need for the treatment of sepsis. According to the World Health Organisation, this condition affects 30 million people every year and could be responsible for as many as six million deaths annually.

The first-in-human study

The phase one trial will test the safety and tolerability of Recce 327 in 40 healthy participants. This will take place at the clinical trial facility separate from the hospital system so as not to place pressure on a system coping with the COVID-19 pandemic.

Recce Pharmaceutical expects that dosing of participants will occur in the second half of 2020 while results should be ready in less than 12 months from now.

In addition, self-dosing by a physician in New South Wales indicated a healthy safety profile. Blood samples were analysed according to clinical biochemistry markers and all results were normal.

By market close, Recce Pharmaceutical shares were up 1.39 per cent to 36.5 cents each.

RCE by the numbers
More From The Market Herald
Heramed (ASX:HMD) - CEO and Co Founder, David Groberman

" HeraMED (ASX:HMD) raises $2.39m via convertible note placement

HeraMED (HMD) has raised roughly $2.39 million through a convertible note placement.
NeuroScientific Biopharmaceuticals (ASX:NSB) - MD and CEO, Matthew Liddelow

" NeuroScientific Biopharmaceuticals (ASX:NSB) completes safety pharmacology studies

NeuroScientific Biopharmaceuticals (NSB) has seen no adverse events during its non-clinical studies of EmtinB.
PharmAust (ASX:PAA) - Chief Scientific Officer, Dr Richard Mollard

" PharmAust (ASX:PAA) identifies optimal MPL dose for canine cancer

Clinical-stage biotech company PharmAust (PAA) has identified the optimum monepantel (MPL) drug plasma range for dogs with B-cell lymphoma.
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion Group (ASX:ALC) extends contract with Sydney Local Health District

Alcidion Group (ALC) has expanded the use of its remote patient monitoring platform, Miya Precision, with the Sydney Local Health District (LHD).